Skye Bioscience Inc. Common Stock (SKYE)

About SKYE

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in periphe…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

2

Website

skyebioscience.com/

Fundamentals

1-day range

$1.76$1.95

Market cap

$20.53M

P/E (trailing)

—

P/E (forward)

-0.22

EPS (trailing)

$-1.45

Dividend yield

—

Beta

2.84

Avg. volume

65.7K

Forecasts

5 analyst ratings

Skye Bioscience Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SKYE

  Skye Bioscience Inc. Common Stock

  $1.81

  ▼ 7.18%
  Market cap $20.53MP/E —
  $1.84$39.92
• MRKR

  Marker Therapeutics Inc. Common Stock

  $1.37

  ▼ 7.12%
  Market cap $20.34MP/E —
  $0.8099$2.46
• PLRZ

  Polyrizon Ltd. Ordinary Shares

  $12.7

  ▼ 0.78%
  Market cap $19.82MP/E —
  $2.88$18.2
• NEUP

  Neuphoria Therapeutics Inc. Common Stock

  $3.82

  ▲ 1.33%
  Market cap $21.24MP/E —
  $3.19$21.4
• CLRB

  Cellectar Biosciences Inc. Common Stock

  $2.54

  ▲ 0.00%
  Market cap $21.26MP/E —
  $2.2$6.52
• ALLR

  Allarity Therapeutics Inc. Common Stock

  $1.41

  ▲ 2.17%
  Market cap $19.64MP/E —
  $0.769$2.06
• DARE

  Dare Bioscience Inc. Common Stock

  $0.7437

  ▲ 0.64%
  Market cap $19.17MP/E —
  $0.72$3.78

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move
  benzinga · 8/26/2026
• Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move
  Benzinga · 8/26/2026
• Skye Bioscience Enters Into Securities Purchase Agreement With Redmile Affiliate For Aggregate Purchase Price Of Up To $22M
  Benzinga · 8/24/2026
• The trading volume of these stocks is deviating from the norm in today's session.
  ChartMill · 8/21/2026
• Unusual volume stocks in Wednesday's session
  ChartMill · 8/19/2026
• Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Fibrex ...
  Yahoo · 8/17/2026
• Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
  Benzinga · 8/17/2026
• Skye Bioscience, Inc. (SKYE) Skye Bioscience, Inc. - M&A Call - Slideshow
  SeekingAlpha · 8/16/2026
• Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
  SeekingAlpha · 8/14/2026

• DHILLON PUNIT · August 7, 2026 · Grant

  1.09M
• Smith Karen L. · March 31, 2026 · Grant

  75.0K
• Twitty Christopher · March 31, 2026 · Disposition

  12.0K
• Twitty Christopher · March 31, 2026 · Grant

  12.0K
• Twitty Christopher · March 31, 2026 · Disposition

  150.0K
• Twitty Christopher · March 31, 2026 · Grant

  150.0K
• Twitty Christopher · March 31, 2026 · Disposition

  200.0K
• Twitty Christopher · March 31, 2026 · Grant

  200.0K
• Twitty Christopher · March 31, 2026 · Disposition

  7.1K
• Twitty Christopher · March 31, 2026 · Grant

  7.1K
• Twitty Christopher · March 31, 2026 · Disposition

  75.0K
• Twitty Christopher · March 31, 2026 · Grant

  75.0K
• Twitty Christopher · March 31, 2026 · Disposition

  17.0K
• Twitty Christopher · March 31, 2026 · Grant

  17.0K
• Jenkins Annalisa · March 31, 2026 · Grant

  75.0K

Institutional Ownership

March 31, 2026

Total shares held

16.12M

Total value held

$9.91M

Institutional holders

37